Company news

Krystal Biotech, Inc. news in 2022

Krystal Biotech, Inc.'s news releases, calls and decks from 2022, newest first.

View company

New England Journal of Medicine Publishes Phase 3 Data on B-VEC in Patients with Dystrophic Epidermolysis Bullosa

December 13, 2022

Jeune Aesthetics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference

December 4, 2022

Krystal Biotech to Present at BofA Securities 2022 Biotech SMID Cap Conference

November 30, 2022

Krystal Biotech to Present at 5th Annual Evercore ISI HealthCONx Conference

November 22, 2022

Jeune Aesthetics Announces Positive Durability Results for KB301 in the PEARL-1 Extension Cohort, an Investigational Gene-based Treatment for Improvement of Fine Lines and Wrinkles

November 16, 2022

Krystal Biotech Announces Third Quarter 2022 Financial Results and Operational Highlights

November 6, 2022

Krystal Biotech to Present at Chardan’s 6th Annual Genetic Medicines Conference

September 28, 2022

Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for B-VEC for the treatment of Dystrophic Epidermolysis Bullosa

September 20, 2022

Krystal Biotech to Present at H.C. Wainwright 24th Annual Global Investment Conference

September 7, 2022

FDA Accepts Krystal Biotech’s Biologics License Application for Dystrophic Epidermolysis Bullosa

August 17, 2022

Krystal Biotech Announces Second Quarter 2022 Financial Results and Reports Updates on Operational Progress

August 7, 2022

Krystal Biotech Announces FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trial

July 31, 2022

Krystal Biotech to Present at William Blair Biotech Focus Conference 2022

July 5, 2022

Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa

June 21, 2022

Krystal Biotech to Present at Goldman Sachs 43rd Annual Global Healthcare Conference

June 6, 2022

Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting

May 18, 2022

Krystal Biotech Announces First Quarter 2022 Financial Results and Reports Updates on Operational Progress

May 8, 2022

Krystal Biotech to Participate in Bank of America Merrill Lynch Global Healthcare Conference

May 2, 2022

Krystal Biotech Announces Home Dosing in B-VEC Open Label Extension Study

April 10, 2022

Krystal Biotech Announces Publication of Phase 1 and 2 Clinical Trial (GEM 1/2 Study) of Beremagene Geperpavec (B-VEC) Data in Nature Medicine

March 27, 2022

New GEM-3 Phase 3 Results for B-VEC Presented at 2022 American Academy of Dermatology Annual Meeting

March 25, 2022

Krystal Biotech to Participate in H.C. Wainwright and Guggenheim Investor Conferences

March 23, 2022

Krystal Biotech to Present at 2022 American Academy of Dermatology Annual Meeting

March 17, 2022

Krystal Biotech Announces Settlement with PeriphaGen, Inc.

March 14, 2022

Krystal Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Operational Progress

February 27, 2022

Krystal Biotech to Participate in Cowen’s 42nd Annual Health Care Conference

February 23, 2022

Krystal Biotech Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand Sutherland, MD, MPH to its Board of Directors

January 17, 2022

Decks in 2022